<?xml version="1.0" encoding="UTF-8"?>
<p>This was a single-arm, phase 1, nonrandomized, single-institution study performed at a tertiary cancer center in the US that was approved by the Memorial Sloan Kettering Cancer Center institutional review board and followed the Transparent Reporting of Evaluations With Nonrandomized Designs (
 <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/trendstatement/" xmlns:xlink="http://www.w3.org/1999/xlink">TREND</ext-link>) reporting guidelines.
 <sup>
  <xref rid="zoi201035r16" ref-type="bibr">16</xref>
 </sup> Written informed consent was obtained for each patient. The full trial protocol is included in 
 <xref ref-type="supplementary-material" rid="note-ZOI201035-1-s">Supplement 1</xref>. A total of 23 patients were enrolled from September 26, 2017, to July 29, 2019, and 20 of 23 patients (87%) had evaluable data (
 <xref ref-type="fig" rid="zoi201035f1">Figure 1</xref>). We included patients with (1) American Joint Committee on Cancer stages IA to IIIC; (2) biopsy-proven, operable invasive breast cancer; (3) tumor bed suitable for post-NAC MRI-guided biopsy as determined by a breast radiologist; (4) completed standard-of-care NAC; (5) completed pre- and post-NAC MRIs; (6) imaging complete response on post-NAC MRI defined as no residual contrast enhancement; and (7) completed definitive surgery at our institution. Exclusion criteria included age less than 18 years, medical reason precluding study participation, and prior history of breast cancer. 
 <xref ref-type="fig" rid="zoi201035f2">Figure 2</xref> is a schematic of this clinical trial.
</p>
